ArticleCancer research communications2023

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.

Hanae Ida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.